Geode Capital Management, LLC Ardelyx, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 5,487,742 shares of ARDX stock, worth $30.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,487,742

Previous 5,470,446 0.32%

Holding current value

$30.7 Million

Previous $40.5 Million 6.72%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$5.28 - $7.57 $91,322 - $130,930	17,296 Added 0.32%	5,487,742 $37.8 Million
Q2 2024 Aug 09, 2024	BUY	$5.89 - $9.31 $1.54 Million - $2.44 Million	261,637 Added 5.02%	5,470,446 $40.5 Million
Q1 2024 May 13, 2024	BUY	$6.05 - $9.74 $1.29 Million - $2.08 Million	213,447 Added 4.27%	5,208,809 $38 Million
Q4 2023 Feb 13, 2024	BUY	$3.29 - $6.64 $1.77 Million - $3.57 Million	537,930 Added 12.07%	4,995,362 $31 Million
Q3 2023 Nov 13, 2023	BUY	$3.3 - $4.83 $796,177 - $1.17 Million	241,266 Added 5.72%	4,457,432 $18.2 Million
Q2 2023 Aug 11, 2023	BUY	$3.23 - $4.95 $7.23 Million - $11.1 Million	2,237,993 Added 113.13%	4,216,166 $14.3 Million
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $673,312 - $1.2 Million	251,236 Added 14.55%	1,978,173 $9.48 Million
Q4 2022 Feb 13, 2023	BUY	$1.22 - $2.85 $352,177 - $822,709	288,670 Added 20.07%	1,726,937 $4.92 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $312,659 - $763,100	529,931 Added 58.34%	1,438,267 $1.71 Million
Q2 2022 Aug 12, 2022	SELL	$0.51 - $1.17 $388,626 - $891,555	-762,013 Reduced 45.62%	908,336 $535,000
Q1 2022 May 13, 2022	BUY	$0.65 - $1.18 $199,148 - $361,530	306,382 Added 22.46%	1,670,349 $1.79 Million
Q4 2021 Feb 11, 2022	SELL	$0.86 - $1.7 $347,733 - $687,379	-404,341 Reduced 22.87%	1,363,967 $1.5 Million
Q3 2021 Nov 12, 2021	BUY	$1.27 - $8.17 $411,365 - $2.65 Million	323,910 Added 22.43%	1,768,308 $2.33 Million
Q2 2021 Aug 13, 2021	BUY	$6.55 - $8.98 $1.04 Million - $1.43 Million	159,076 Added 12.38%	1,444,398 $10.9 Million
Q1 2021 May 12, 2021	BUY	$6.1 - $7.69 $757,461 - $954,898	124,174 Added 10.69%	1,285,322 $8.51 Million
Q4 2020 Feb 12, 2021	BUY	$5.05 - $7.1 $160,433 - $225,559	31,769 Added 2.81%	1,161,148 $7.51 Million
Q3 2020 Nov 13, 2020	BUY	$5.25 - $7.08 $125,165 - $168,794	23,841 Added 2.16%	1,129,379 $5.93 Million
Q2 2020 Aug 13, 2020	BUY	$5.37 - $8.11 $532,258 - $803,838	99,117 Added 9.85%	1,105,538 $7.65 Million
Q1 2020 May 14, 2020	BUY	$4.35 - $8.79 $779,533 - $1.58 Million	179,203 Added 21.66%	1,006,421 $5.72 Million
Q4 2019 Feb 13, 2020	BUY	$4.23 - $8.29 $593,079 - $1.16 Million	140,208 Added 20.41%	827,218 $6.21 Million
Q3 2019 Nov 12, 2019	BUY	$2.15 - $6.28 $150,693 - $440,165	70,090 Added 11.36%	687,010 $3.23 Million
Q2 2019 Aug 14, 2019	SELL	$2.49 - $3.73 $81,512 - $122,105	-32,736 Reduced 5.04%	616,920 $1.66 Million
Q1 2019 May 14, 2019	SELL	$1.88 - $3.35 $57,665 - $102,754	-30,673 Reduced 4.51%	649,656 $1.82 Million
Q4 2018 Feb 13, 2019	BUY	$1.66 - $4.16 $73,777 - $184,887	44,444 Added 6.99%	680,329 $1.22 Million
Q3 2018 Nov 13, 2018	BUY	$3.75 - $4.65 $409,132 - $507,324	109,102 Added 20.71%	635,885 $2.77 Million
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $914,125 - $1.43 Million	247,061 Added 88.32%	526,783 $1.95 Million
Q1 2018 May 15, 2018	SELL	$5.05 - $7.9 $58,372 - $91,316	-11,559 Reduced 3.97%	279,722 $1.41 Million
Q4 2017 Feb 13, 2018	SELL	$4.85 - $7.8 $24,327 - $39,124	-5,016 Reduced 1.69%	291,281 $1.92 Million
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $482,497 - $632,238	110,919 Added 59.83%	296,297 $1.66 Million
Q2 2017 Aug 14, 2017	BUY	N/A	185,378	185,378 $945,000

Others Institutions Holding ARDX

# of Institutions

219

Shares Held

141M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $864M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Ardelyx, Inc. Transaction History